GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ascentage Pharma Group International (HKSE:06855) » Definitions » Cash, Cash Equivalents, Marketable Securities

Ascentage Pharma Group International (HKSE:06855) Cash, Cash Equivalents, Marketable Securities : HK$1,184.5 Mil (As of Jun. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Ascentage Pharma Group International Cash, Cash Equivalents, Marketable Securities?

Ascentage Pharma Group International's quarterly cash, cash equivalents, marketable securities declined from Jun. 2023 (HK$1,729.92 Mil) to Dec. 2023 (HK$1,169.57 Mil) but then increased from Dec. 2023 (HK$1,169.57 Mil) to Jun. 2024 (HK$1,184.54 Mil).

Ascentage Pharma Group International's annual cash, cash equivalents, marketable securities declined from Dec. 2021 (HK$2,090.03 Mil) to Dec. 2022 (HK$1,647.87 Mil) and declined from Dec. 2022 (HK$1,647.87 Mil) to Dec. 2023 (HK$1,169.57 Mil).


Ascentage Pharma Group International Cash, Cash Equivalents, Marketable Securities Historical Data

The historical data trend for Ascentage Pharma Group International's Cash, Cash Equivalents, Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ascentage Pharma Group International Cash, Cash Equivalents, Marketable Securities Chart

Ascentage Pharma Group International Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash, Cash Equivalents, Marketable Securities
Get a 7-Day Free Trial 977.56 1,209.12 2,090.03 1,647.87 1,169.57

Ascentage Pharma Group International Semi-Annual Data
Dec16 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Cash, Cash Equivalents, Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,991.22 1,647.87 1,729.92 1,169.57 1,184.54

Ascentage Pharma Group International Cash, Cash Equivalents, Marketable Securities Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.


Ascentage Pharma Group International  (HKSE:06855) Cash, Cash Equivalents, Marketable Securities Explanation

Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.


Ascentage Pharma Group International Cash, Cash Equivalents, Marketable Securities Related Terms

Thank you for viewing the detailed overview of Ascentage Pharma Group International's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.


Ascentage Pharma Group International Business Description

Industry
Traded in Other Exchanges
Address
68 Xinqing Road, Suzhou Industrial Park, Jiangsu, Suzhou, CHN, 215000
Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The company's geographical segments include the United States and Mainland China.
Executives
Ascentage Limited
Gao Sharon Xia
Guo Edward Ming
Healthquest Pharma Limited
Li Ju-yun
Wang Shaomeng
Yang Dajun
Zhai Yifan
South Dakota Trust Company Llc 2301 Trustee
Jpmorgan Chase & Co. 2201 Interest of corporation controlled by you
Tian Yuan 2201 Interest of corporation controlled by you
Zhao Li 2202 Interest of your spouse
Xian Jin Zhi Zao Chan Ye Tou Zi Ji Jin You Xian He Huo 2201 Interest of corporation controlled by you
Xian Jin Zhi Zao Chan Ye Tou Zi You Xian Gong Si 2101 Beneficial owner
Guo Tou Chuang Xin Tou Zi Guan Li You Xian Gong Si 2201 Interest of corporation controlled by you

Ascentage Pharma Group International Headlines

No Headlines